Humacyte, Inc. (HUMA): who owns it and who trades it
As of Nov 16, 2026, HUMA insiders reported 1 open-market sale worth $41.3K and 5 purchases worth $90K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Dale A. Sander (CFO), with $41.3K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Humacyte
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns HUMA
163 funds and institutions reported HUMA shares worth $58.2M at the end of Q2 2026, about 34% of the company. The largest holder is Vanguard Capital Management LLC with 4.6%.
Funds and institutions (13F) 34%Everyone else 66%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 10.11M | 4.55% | $7.9M | +41% |
| ANTIPODES PARTNERS Ltd | 10.10M | 4.55% | $7.9M | +77% |
| Alyeska Investment Group, L.P. | 6.02M | 2.71% | $4.7M | – |
| Davidson Kempner Capital Management LP | 5.00M | 2.25% | $3.9M | – |
| BlackRock, Inc. | 4.84M | 2.18% | $3.8M | -61% |
| Great Point Partners LLC | 3.75M | 1.69% | $2.9M | No change |
| UBS Group AG | 2.84M | 1.28% | $2.2M | +2% |
| AQR Capital Management LLC | 2.60M | 1.17% | $2M | +35% |
| Geode Capital Management, LLC | 2.19M | 0.98% | $1.7M | -40% |
| Millennium Management LLC | 1.91M | 0.86% | $1.5M | +1665% |
| Susquehanna International Group, LLP | 1.70M | 0.77% | $1.3M | +61% |
| Citadel Advisors LLC | 1.44M | 0.65% | $1.1M | – |
| Charles Schwab Investment Management Inc | 1.35M | 0.61% | $1.1M | +5% |
| Sixth Street Partners Management Company, L.P. | 1.35M | 0.61% | $1.1M | – |
| Vanguard Fiduciary Trust Co | 1.18M | 0.53% | $921K | +17% |
| Hrt Financial LP | 1.09M | 0.49% | $850K | – |
| LPL Financial LLC | 1.03M | 0.46% | $800K | +19% |
| Gsa Capital Partners LLP | 1.01M | 0.45% | $785K | +303% |
| Private Advisor Group, LLC | 965,091 | 0.43% | $753K | +16% |
| State Street Corp | 842,537 | 0.38% | $658K | -72% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, HUMA insiders reported $90K of open-market purchases and $41.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Keith Anthony Jones | Director | Purchase | 10,000 | $0.56 | $5.6K | Form 4 |
| Aug 20, 2026 | Keith Anthony Jones | Director | Purchase | 10,000 | $0.69 | $6.9K | Form 4 |
| Aug 17, 2026 | Keith Anthony Jones | Director | Purchase | 30,000 | $0.59 | $17.7K | Form 4 |
| May 19, 2026 | Kathleen Sebelius | Director | Purchase | 56,818 | $0.88 | $50K | Form 4 |
| May 18, 2026 | Michael T. Constantino | Director | Purchase | 11,000 | $0.89 | $9.8K | Form 4 |
| May 18, 2026 | Dale A. Sander | CFO | Sale | 45,887 | $0.90 | $41.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kathleen Sebelius | Director | $50K | – | May 19, 2026 |
| Dale A. Sander | CFO and Chief Corp. Dev. Off | – | $41.3K | May 18, 2026 |
| Keith Anthony Jones | Director | $30.2K | – | Sep 14, 2026 |
| Michael T. Constantino | Director | $9.8K | – | May 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HUMA short interest
High short interest. 10.1% of HUMA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 32%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 28.07M HUMA shares were sold short, 10.1% of the shares outstanding, down 7.2% from the report before. At the average daily volume of 3.91M shares, buying them all back would take about 7.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 28.07M | 10.11% | -7% | 3.91M | 7.2 |
| Oct 15, 2026 | 30.25M | 10.89% | +3% | 8.27M | 3.7 |
| Sep 30, 2026 | 29.40M | 10.58% | -8% | 4.02M | 7.3 |
| Sep 15, 2026 | 31.81M | 11.45% | +7% | 4.39M | 7.2 |
| Aug 31, 2026 | 29.81M | 10.73% | -7% | 8.76M | 3.4 |
| Aug 14, 2026 | 31.94M | 11.50% | +1% | 9.50M | 3.4 |
| Jul 31, 2026 | 31.49M | 14.18% | -2% | 4.55M | 6.9 |
| Jul 15, 2026 | 32.28M | 14.54% | +2% | 9.66M | 3.3 |
| Jun 30, 2026 | 31.60M | 14.23% | -14% | 25.18M | 1.2 |
| Jun 15, 2026 | 36.71M | 16.53% | -9% | 8.95M | 4.1 |
| May 29, 2026 | 40.14M | 18.08% | -2% | 6.54M | 6.1 |
| May 15, 2026 | 41.16M | 18.54% | -8% | 7.93M | 5.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Humacyte company events
Humacyte filed 16 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Sep 28, 2026LeadershipThe Board of Directors of Humacyte, Inc., appointed Scott Coward and Paul Kuznik to the Board. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jul 31, 2026ListingHumacyte, Inc. received a letter from the staff of The Nasdaq Stock Market LLC providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid price for the Company’s common stock, par value $0.0001 per share, had closed below the minimum $1.00 per share requirement… Filing
- Jun 11, 2026AgreementOn June 10, 2026, Humacyte, Inc. entered into an underwriting agreement with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in an… Filing
- Jun 10, 2026AnnouncementHumacyte, Inc. issued a press release announcing the presentation of results from its Phase 3 clinical trial (V012) of the acellular tissue engineered vessel (ATEV) in arteriovenous access for female patients with end-stage renal disease requiring hemodialysis. Filing
- Jun 9, 2026VoteReported shareholder vote results. Filing
- Jun 5, 2026AnnouncementAs previously disclosed, on May 4, 2026, Humacyte, Inc. received a letter from the staff of The Nasdaq Stock Market LLC providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price for the Company’s common stock had closed below the minimum $1.00 per share… Filing
- May 8, 2026ListingHumacyte, Inc. received a letter from the staff of The Nasdaq Stock Market LLC providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price for the Company’s common stock, par value $0.0001 per share, had closed below the minimum $1.00 per share requirement for… Filing
- Apr 24, 2026AgreementHumacyte, Inc. entered into the Third Amendment to Distribution Agreement with Fresenius Medical Care Holdings, Inc., to amend the Distribution Agreement, dated as of June 25, 2018, as amended, between the Company and Fresenius. Filing
- Mar 19, 2026AgreementHumacyte, Inc. entered into certain securities purchase agreements pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering 25,000,000 shares of the Company’s common stock, $0.0001 par value per share, at a price of $0.80 per share. Filing
- Mar 19, 2026AnnouncementBelow, is incorporated herein by reference. Filing
- Dec 16, 2025AgreementHumacyte, Inc. entered into a Sales Agreement with TD Securities (USA) LLC, as agent, under which the Company may offer and sell its common stock, par value $0.0001 per share, from time to time having an aggregate offering price of up to $60,000,000 during the term of the Agreement through TD… Filing
- Dec 15, 2025AgreementHumacyte, Inc. and Humacyte Global, Inc., a wholly-owned subsidiary of the Company, entered into a loan and security agreement with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders and as lender, which provides for a senior secured term loan… Filing
- Dec 15, 2025AgreementEnded an important agreement. Filing
- Nov 26, 2025AgreementEnded an important agreement. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Humacyte financials
Famous investors that hold HUMA
3 of the 50 well-known investors we track reported holding HUMA in their latest 13F filing. The largest position is Ken Griffin's, worth $897K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.73M | $897K | 0.0% | +20% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 110,271 | $57.1K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 12,300 | $6.4K | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Humacyte, Inc. (HUMA) stock
Who owns the most HUMA stock?
The largest reported owner of Humacyte, Inc. (HUMA) is Vanguard Capital Management LLC, with 4.6% of the company. In total, 163 funds and institutions reported holding HUMA at the end of Q2 2026, together about 34% of the shares. See the largest owners.
Are HUMA insiders buying or selling?
In the last 12 months, HUMA insiders reported 5 open-market purchases worth $90K and 1 sale worth $41.3K. The latest trade was on Sep 14, 2026. See every trade.
What is the short interest in HUMA?
As of Oct 30, 2026, 28.07M HUMA shares were sold short, 10.1% of the shares outstanding, down 7.2% from the report before. At the average daily volume of 3.91M shares, buying them all back would take about 7.2 trading days (days to cover). See the history.
Which famous investors hold HUMA?
3 of the 50 well-known investors we track reported HUMA in their latest 13F filing, including Ken Griffin, Jim Simons, Paul Tudor Jones. The largest position is worth $897K. See all holders.
Executive pay
Humacyte's chief executive was paid a total of $5.2M for the year ended Dec 31, 2025, up 478% from $905K the year before. In the last 12 months, Humacyte's executives and directors bought $90K of stock on the open market and sold $41.3K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.